Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q2 CY2026, with sales up 13% year on year to $12.59 billion. Its non-GAAP profit of $1.31 per share was 2.6% above analysts’ ...

Abbott Laboratories (NYSE:ABT) plans to separate its Nutrition segment into an independent publicly traded company, targeting ...

Abbott Laboratories has seen a mixed share price record in recent years, which raises a straightforward question for anyone ...

Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition ...

Abbott Laboratories (ABT) delivered a strong Q2 2026 performance that surprised Wall Street, with the healthcare giant posting a double beat on both top and bottom lines on July 16, 2026. The earnings ...

Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) in Q3 2026, with sales up 14.5% year on year to $13.01 ...

SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary ...

Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show ...

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Healthcare product and device company Abbott ...